PharVision Advisers’s Steelcase SCS Stock Holding History

PharVision Advisers’s Portfolio SCS Stock Details SCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-32,688	Closed	-$386K	–	485
2024 Q4	$386K	Buy	+32,688	New	+$421K	0.33%	87

Other funds holding SCS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's SCS Position: Q1 2025 in Review

PharVision Advisers sold out of Steelcase (SCS) in Q1 2025, closing a stake of 32,688 shares — an estimated $386K sold.

PharVision Advisers first reported a position in SCS in Q4 2024 and held it in 1 quarter. The position peaked at $386K in Q4 2024. 233 funds tracked by Wall St. Rank hold SCS as of Q1 2025.

PharVision Advisers reported no remaining Steelcase position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 32,688 Steelcase shares in Q1 2025, an estimated $386K.
PharVision Advisers first reported a position in Steelcase in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Steelcase position peaked at $386K in Q4 2024.
233 funds tracked by Wall St. Rank held Steelcase as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.